Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production
Martires, Kathryn J. Capaldi, Laura Pattee, Sean F. Maloney, Mary E. Bordeaux, Jeremy S.
Martires, Kathryn J.
Capaldi, Laura
Pattee, Sean F.
Maloney, Mary E.
Bordeaux, Jeremy S.
Citations
Altmetric:
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Letter to the Editor
Publication Date
2010-09-01
Keywords
Administration, Topical
Aminoquinolines
Biopsy, Needle
Female
Follow-Up Studies
Humans
Hutchinson's Melanotic Freckle
Immunohistochemistry
Melanoma, Amelanotic
Middle Aged
Neoplasm Recurrence, Local
Nose
Risk Assessment
Skin Neoplasms
Treatment Outcome
Dermatology
Skin and Connective Tissue Diseases
Aminoquinolines
Biopsy, Needle
Female
Follow-Up Studies
Humans
Hutchinson's Melanotic Freckle
Immunohistochemistry
Melanoma, Amelanotic
Middle Aged
Neoplasm Recurrence, Local
Nose
Risk Assessment
Skin Neoplasms
Treatment Outcome
Dermatology
Skin and Connective Tissue Diseases
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
A melanotic lentigo maligna (ALM) represents a small subset of lentigo maligna (LM) that lacks pigment. At least 2 cases of ALM responsive to imiquimod therapy with short-term follow-up have been reported. We report herein a case of ALM that failed to respond to imiquimod treatment. Furthermore, after therapy was initiated, the ALM began to produce pigment and transformed to LM.
Source
Martires KJ, Capaldi L, Pattee SF, Maloney ME, Bordeaux JS. Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production. Arch Dermatol. 2010 Sep;146(9):1047-8. doi: 10.1001/archdermatol.2010.237.
Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1001/archdermatol.2010.237
Permanent Link to this Item
PubMed ID
20855714